Neuberger Berman Group Portfolio holdings
Neuberger Berman is an employee-owned investment manager that runs stock, bond, private equity and hedge fund portfolios for institutions, advisers and high net worth individuals. Art collector Roy Neuberger and banker Robert Berman co-founded the firm in 1939. Lehman Brothers bought it in 2003, and after Lehman collapsed in 2008 the firm's own managers won a bankruptcy auction for it, spinning it off in 2009 and returning it to full employee ownership by the end of 2014. Since going independent it has moved beyond its traditional focus on stocks into emerging markets debt, high-yield bonds and private equity, and in 2024 it led a private equity group that agreed to buy the school operator Nord Anglia Education. Art has been part of the firm's workplace culture since Roy Neuberger co-founded it, and it bought back many pieces of its collection at auction in 2010 after Lehman had absorbed them.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$463M |
| 2 |
Apple
AAPL
|
+$418M |
| 3 |
SpaceX
SPCX
|
+$361M |
| 4 |
NVIDIA
NVDA
|
+$291M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$285M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$428M |
| 2 |
Microsoft
MSFT
|
+$314M |
| 3 |
Boston Scientific
BSX
|
+$269M |
| 4 |
Teradyne
TER
|
+$249M |
| 5 |
T-Mobile US
TMUS
|
+$246M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.73% |
| 2 | Financials | 12.28% |
| 3 | Industrials | 12.11% |
| 4 | Healthcare | 8.91% |
| 5 | Consumer Discretionary | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2276
Altimmune
ALT
$344M
| $56.7K | ﹤0.01% |
+18,664
| New | +$55.7K |
2026 Q2
0 quarters
|
|
2277
Atea Pharmaceuticals
AVIR
$332M
| $56.2K | ﹤0.01% |
+12,077
| New | +$60.1K |
2026 Q2
0 quarters
|
|
2278
Allogene Therapeutics
ALLO
$302M
| $55.8K | ﹤0.01% |
26,835
+12,010
| +81% | +$26.4K |
2026 Q1
1 quarter
|
|
2279
Evolent Health
EVH
$552M
| $55.2K | ﹤0.01% |
+10,177
| New | +$39K |
2026 Q2
0 quarters
|
|
2280
B&G Foods
BGS
$290M
| $53.9K | ﹤0.01% |
13,545
+265
| +2% | +$1.23K |
2025 Q2
4 quarters
|
|
2281
Hyliion Holdings
HYLN
$469M
| $52.8K | ﹤0.01% |
10,136
-290
| -3% | -$1.21K |
2025 Q3
3 quarters
|
|
2282
Ironwood Pharmaceuticals
IRWD
$810M
| $52.4K | ﹤0.01% |
12,448
-62
| -0.5% | -$239 |
2024 Q4
6 quarters
|
|
2283
Eledon Pharmaceuticals
ELDN
$202M
| $52.2K | ﹤0.01% |
+13,246
| New | +$48.2K |
2026 Q2
0 quarters
|
|
2284
Perspective Therapeutics
CATX
$102M
| $52.1K | ﹤0.01% |
+15,284
| New | +$57.7K |
2026 Q2
0 quarters
|
|
2285
James River Group Holdings
JRVR
$143M
| $51.7K | ﹤0.01% |
+11,754
| New | +$57.8K |
2026 Q2
0 quarters
|
|
2286
Playtika
PLTK
$980M
| $50K | ﹤0.01% |
13,439
+3,137
| +30% | +$10.8K |
2025 Q4
2 quarters
|
|
2287
Ares Commercial Real Estate
ACRE
$199M
| $45.7K | ﹤0.01% |
10,156
-449
| -4% | -$2.22K |
2025 Q4
2 quarters
|
|
2288
Fate Therapeutics
FATE
$152M
| $45.1K | ﹤0.01% |
16,696
+1,346
| +9% | +$2.49K |
2025 Q4
2 quarters
|
|
2289
Organogenesis Holdings
ORGO
$125M
| $44.4K | ﹤0.01% |
+18,255
| New | +$44.6K |
2026 Q2
0 quarters
|
|
2290
Cricut
CRCT
$1.81B
| $44.3K | ﹤0.01% |
+10,092
| New | +$43.2K |
2026 Q2
0 quarters
|
|
2291
Stitch Fix
SFIX
$377M
| $44K | ﹤0.01% |
+10,716
| New | +$39K |
2026 Q2
0 quarters
|
|
2292
DELISTED
Esperion Therapeutics
ESPR
| $43.6K | ﹤0.01% |
13,798
+956
| +7% | +$2.67K |
2025 Q4
2 quarters
|
|
2293
Compass Therapeutics
CMPX
$144M
| $43.3K | ﹤0.01% |
19,792
+3,439
| +21% | +$10.2K |
2025 Q4
2 quarters
|
|
2294
Inhibikase Therapeutics
IKT
$211M
| $43.2K | ﹤0.01% |
+21,293
| New | +$38.1K |
2026 Q2
0 quarters
|
|
2295
Cerus
CERS
$408M
| $43K | ﹤0.01% |
14,741
+867
| +6% | +$2.1K |
2024 Q2
8 quarters
|
|
2296
Sana Biotechnology
SANA
$635M
| $42.1K | ﹤0.01% |
12,066
-2,261
| -16% | -$7.28K |
2025 Q1
5 quarters
|
|
2297
Braemar Hotels & Resorts
BHR
$115M
| $40.5K | ﹤0.01% |
18,755
+4,660
| +33% | +$11.2K |
2025 Q4
2 quarters
|
|
2298
Anavex Life Sciences
AVXL
$91.8M
| $39.3K | ﹤0.01% |
+15,188
| New | +$44.9K |
2026 Q2
0 quarters
|
|
2299
TH International
THCH
$39.1M
| $38.1K | ﹤0.01% |
19,937
| – | – |
2026 Q1
1 quarter
|
|
2300
Akebia Therapeutics
AKBA
$151M
| $37.8K | ﹤0.01% |
+33,143
| New | +$39.5K |
2026 Q2
0 quarters
|
|
Similar funds
Neuberger Berman Group's Q2 2026 Portfolio in Review
As of Q2 2026, Neuberger Berman Group held 2,421 positions worth $150B, up 14% from $131B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Neuberger Berman Group's Q2 2026 filing shows 259 new, 1,157 increased, 848 reduced and 81 closed positions. Its largest new stake was SpaceX: 2,127,228 shares worth $363M. The largest sale was Advanced Micro Devices, an estimated $428M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 25% a quarter earlier, followed by Financials and Industrials.
- Neuberger Berman Group's largest Q2 2026 buy was SpaceX: 2,127,228 shares worth $363M.
- Neuberger Berman Group added most to Amazon in Q2 2026, an estimated $463M increase.
- Neuberger Berman Group's biggest Q2 2026 reduction was Advanced Micro Devices, cutting an estimated $428M.
- Neuberger Berman Group fully exited Hologic in Q2 2026, selling an estimated $103M.
- Neuberger Berman Group's ten largest holdings make up 23% of its $150B portfolio in Q2 2026.
- Neuberger Berman Group opened 259 new positions and closed 81 in Q2 2026.
- Neuberger Berman Group's portfolio value rose 14% quarter-over-quarter to $150B.
Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.